id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-000904-g6ffaer1	Ni, Hong	Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma	2011-09-17		.txt	text/plain	3449	186	46	OBJECTIVE: To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable advanced HCC received cryoablation and sorafenib at a dose of 400 mg twice daily in 4-week cycles on the same day of the cryoablation. CONCLUSION: Cryoablation combined with sorafenib demonstrates good efficacy and acceptable tolerability in treating unresectable advanced HCC patients. Among patients with advanced disease who do not qualify for surgical or liver transplantation therapies, the only non-chemotherapeutic treatment that has been shown to increase survival is sorafenib [6] . In this paper, we report the results of our prospective study conducted to evaluate the efficacy and acceptable tolerability of sorafenib as adjuvant treatment after cryoablation in the treatment of unresectable HCC. However, all other patients and tumor characteristics, including age, sex, ECOG performance status, Child-Pugh class, ongoing antiviral therapy, BCLC stage, and prior systemic treatment had no effect on clinical benefits.	./cache/cord-000904-g6ffaer1.txt	./txt/cord-000904-g6ffaer1.txt